MLANA and melanoma: On the other hand, NEDDL also shows an oncogenic activity with a highly elevated expression in cutaneous T-cell lymphoma (Booken et al. 2008), gallbladder cancer (by modulating the transcription of matrix metalloproteinase genes MMP-1 and MMP-13) (Takeuchi et al. 2011), prostate carcinoma (by ubiquitination and degradation of TGF-β) (Hellwinkel et al. 2011), and melanoma (Kito et al. 2014) [by ubiquitination and degradation of melanosomal transmembrane protein Melan-A/MART-1 (Lévy et al. 2005)].